Alvotech (ALVO) Stock Price, Quote & News

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg

ZacksResearch Sep. 9 at 1:51 PM

$ALVO near 52-week low — time to buy the dip or hold? 🤔 📉 38% YTD decline against industry’s 5% growth 🤝 Strategic partnerships with TEVA & RDY drive over 200% increase in product revenues in 1H 2025 📈 Rising EPS estimates and a Zacks Rank #3 (Hold) suggest growth potential Discover the full analysis here 👉 https://www.zacks.com/stock/news/2748596/alvo-stock-trades-near-52-week-low-should-you-buy-hold-or-sell?cid=sm-stocktwits-2-2748596-body-11480&ADID=SYND_STOCKTWITS_TWEET_2_2748596_BODY_11480

0 · Reply

ZacksResearch Sep. 9 at 12:51 PM

$ALVO near its 52-week low — bargain or falling knife? ⚡️ The stock is trading close to its yearly bottom, putting investors in a tough spot: buy, hold, or sell at these levels. Full breakdown here 👉 https://www.zacks.com/stock/news/2748596/alvo-stock-trades-near-52-week-low-should-you-buy-hold-or-sell?cid=sm-stocktwits-2-2748596-teaser-11469&ADID=SYND_STOCKTWITS_TWEET_2_2748596_TEASER_11469

0 · Reply

Thestocktraderhubzee Aug. 21 at 9:46 AM

WATCHLIST AUG 21 2025 $INSG Inseego Corp And OneSource Enters Partnership To Launch Janus, A New Managed Service That Combines Inseego's 5G Fixed Wireless Access Devices With OneSource's Connectivity Services $NAMS NewAmsterdam Pharma And Piramal Pharma Solutions Invest Multi-Million Dollars In Dedicated Oral Solid Dosage Suite At Sellersville Pennsylvania Facility $ALVO Advanz Pharma And Alvotech Receive European Commission Approval For Mynzepli Biosimilar To Eylea For Treatment Of Retinal Diseases Including Neovascular AMD $WRD WeRide Teams With Bosch To Launch Human-Like One-Stage Driving Tech, Plans Mass Production In 2025 $CECO Needham Maintains Buy on CECO Environmental, Raises Price Target to $52

0 · Reply

saad545 Aug. 21 at 9:33 AM

$ALVO https://finance.yahoo.com/news/advanz-pharma-alvotech-receive-european-083000775.html

0 · Reply

saad545 Aug. 18 at 2:20 PM

$ALVO

0 · Reply

TravelingTraderNL Aug. 14 at 7:01 PM

$ALVO +12% from day low

0 · Reply

TravelingTraderNL Aug. 14 at 6:43 PM

$ALVO +10% from day low

0 · Reply

TravelingTraderNL Aug. 14 at 5:27 PM

$ALVO green end of day

0 · Reply

TravelingTraderNL Aug. 14 at 5:21 PM

$ALVO +9% from day low

0 · Reply

saad545 Aug. 14 at 4:49 PM

$ALVO

0 · Reply

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 9:15 AM EDT - 9 days ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Aug 21, 2025, 4:30 AM EDT - 23 days ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 20, 2025, 6:05 AM EDT - 24 days ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 14, 2025, 11:38 AM EDT - 4 weeks ago

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:15 PM EDT - 4 weeks ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 4 weeks ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 6, 2025, 8:00 AM EDT - 5 weeks ago

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Jul 10, 2025, 4:40 AM EDT - 2 months ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 9, 2025, 4:30 AM EDT - 2 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 2 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 3, 2025, 7:02 PM EDT - 2 months ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Jul 1, 2025, 7:54 PM EDT - 2 months ago

Granting of Stock Options and Vesting of Restricted Share Units

Jul 1, 2025, 4:00 AM EDT - 2 months ago

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Jun 26, 2025, 4:15 AM EDT - 2 months ago

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Jun 25, 2025, 4:45 PM EDT - 2 months ago

Main Results of 2025 Annual and Extraordinary General Meeting

Jun 25, 2025, 4:00 AM EDT - 2 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 2 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 23, 2025, 4:00 AM EDT - 2 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 2 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 11, 2025, 4:20 PM EDT - 3 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 11, 2025, 4:18 PM EDT - 3 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 6, 2025, 8:30 AM EDT - 3 months ago

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 3 months ago

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Jun 5, 2025, 1:56 PM EDT - 3 months ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

MRK RDY

Jun 4, 2025, 10:29 PM EDT - 3 months ago

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Jun 4, 2025, 11:32 AM EDT - 3 months ago

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Jun 4, 2025, 7:45 AM EDT - 3 months ago

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Jun 2, 2025, 9:15 AM EDT - 3 months ago

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

May 28, 2025, 6:15 AM EDT - 3 months ago

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

May 26, 2025, 2:06 PM EDT - 3 months ago

Alvotech Annual General Meeting to be held June 25, 2025

May 23, 2025, 12:11 PM EDT - 4 months ago

Transactions of Managers and Closely Associated Persons

May 19, 2025, 3:15 AM EDT - 4 months ago

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

May 19, 2025, 2:30 AM EDT - 4 months ago

Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today

May 16, 2025, 1:52 PM EDT - 4 months ago

Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm

May 11, 2025, 1:08 AM EDT - 4 months ago

Alvotech (ALVO) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:30 AM EDT - 4 months ago

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

May 7, 2025, 4:45 PM EDT - 4 months ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 4:45 PM EDT - 4 months ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 5:00 AM EDT - 4 months ago

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

May 2, 2025, 8:30 AM EDT - 4 months ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

May 2, 2025, 8:30 AM EDT - 4 months ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Apr 30, 2025, 4:39 PM EDT - 4 months ago

Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)

Mar 28, 2025, 5:01 PM EDT - 6 months ago

This Is a Test From GlobeNewswire

CMPS

Mar 27, 2025, 12:09 PM EDT - 6 months ago

Alvotech (ALVO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:30 AM EDT - 6 months ago

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Mar 26, 2025, 6:36 PM EDT - 6 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 6:34 PM EDT - 6 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 4:30 AM EDT - 6 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 26, 2025, 4:30 AM EDT - 6 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

ZacksResearch Sep. 9 at 1:51 PM

0 · Reply

ZacksResearch Sep. 9 at 12:51 PM

0 · Reply

Thestocktraderhubzee Aug. 21 at 9:46 AM

0 · Reply

saad545 Aug. 21 at 9:33 AM

$ALVO https://finance.yahoo.com/news/advanz-pharma-alvotech-receive-european-083000775.html

0 · Reply

saad545 Aug. 18 at 2:20 PM

$ALVO

0 · Reply

TravelingTraderNL Aug. 14 at 7:01 PM

$ALVO +12% from day low

0 · Reply

TravelingTraderNL Aug. 14 at 6:43 PM

$ALVO +10% from day low

0 · Reply

TravelingTraderNL Aug. 14 at 5:27 PM

$ALVO green end of day

0 · Reply

TravelingTraderNL Aug. 14 at 5:21 PM

$ALVO +9% from day low

0 · Reply

saad545 Aug. 14 at 4:49 PM

$ALVO

0 · Reply

TravelingTraderNL Aug. 14 at 4:41 PM

$ALVO +7% from day low

0 · Reply

TravelingTraderNL Aug. 14 at 4:23 PM

$ALVO +4% from day low

0 · Reply

TravelingTraderNL Aug. 14 at 2:49 PM

$ALVO paper hands are out. let's run

0 · Reply

Pianomemo Aug. 14 at 2:01 PM

$ALVO net income profits from here on

0 · Reply

saad545 Aug. 14 at 1:32 PM

$ALVO why dropping?

1 · Reply

TravelingTraderNL Aug. 13 at 8:34 PM

$ALVO eps 0.5 in 6 months => PE 9 200% growth in product revenues yoy Super cheap growth stock!

1 · Reply

Zhezha Aug. 13 at 8:11 PM

$ALVO what time is the earnings ?

1 · Reply

TravelingTraderNL Aug. 13 at 7:51 PM

$ALVO want to see +20% on earninsg, like q1

0 · Reply

MGeronimo Aug. 10 at 9:50 PM

$ALVO BACK IN AT 8.46

0 · Reply

Zhezha Aug. 7 at 4:35 PM

$ALVO me, still talking to myself

1 · Reply

Zhezha Jul. 30 at 3:14 PM

$ALVO slow

0 · Reply

ZacksResearch Jul. 30 at 3:07 PM

$ALVO's Q2 earnings: Will the impressive surprise history continue? Despite a strong earnings surprise history, delivering an average surprise of 244.18%, ALVO's current setup might not support another beat. The Earnings ESP stands at 0.00%. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2638948/alvotech-gears-up-to-report-q2-earnings-heres-what-to-expect?cid=sm-stocktwits-2-2638948-body-4796&ADID=SYND_STOCKTWITS_TWEET_2_2638948_BODY_4796

0 · Reply

Market Cap	2.42B
Revenue (ttm)	489.68M
Net Income (ttm)	-231.86M
EPS (ttm)	N/A
PE Ratio	18.30
Forward PE	35.85
Profit Margin	-47.35%
Debt to Equity Ratio	-6.45

Volume	221,200
Avg Vol	387,638
Day's Range	N/A - N/A
Shares Out	301.48M
Stochastic %K	32%
Beta	0.10
Analysts	Sell
Price Target	$17.50